DK1698640T4 - Fremgangsmåde til stabilisering af antistof og antistofpræparat som stabiliseret opløsning. - Google Patents

Fremgangsmåde til stabilisering af antistof og antistofpræparat som stabiliseret opløsning. Download PDF

Info

Publication number
DK1698640T4
DK1698640T4 DK04773700.2T DK04773700T DK1698640T4 DK 1698640 T4 DK1698640 T4 DK 1698640T4 DK 04773700 T DK04773700 T DK 04773700T DK 1698640 T4 DK1698640 T4 DK 1698640T4
Authority
DK
Denmark
Prior art keywords
antibody
procedure
stabilizing
stabilized solution
preparation
Prior art date
Application number
DK04773700.2T
Other languages
English (en)
Other versions
DK1698640T3 (da
Inventor
Yuji C/O Kyowa Hakko Kogyo Co Ltd Ueno
Takashi C/O Kyowa Hakko Kogyo Co Ltd Kayashita
Atsushi C/O Kyowa Hakko Kogyo Co Ltd Ishihara
Masashi C/O Kyowa Hakko Kogyo Co Ltd Nakakura
Kyoko C/O Kyowa Hakko Kogyo Co Ltd Yamauchi
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34419308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1698640(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of DK1698640T3 publication Critical patent/DK1698640T3/da
Application granted granted Critical
Publication of DK1698640T4 publication Critical patent/DK1698640T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK04773700.2T 2003-10-01 2004-10-01 Fremgangsmåde til stabilisering af antistof og antistofpræparat som stabiliseret opløsning. DK1698640T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003343645 2003-10-01
PCT/JP2004/014903 WO2005033143A1 (ja) 2003-10-01 2004-10-01 抗体の安定化方法及び安定化された溶液状抗体製剤

Publications (2)

Publication Number Publication Date
DK1698640T3 DK1698640T3 (da) 2016-02-15
DK1698640T4 true DK1698640T4 (da) 2019-09-02

Family

ID=34419308

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04773700.2T DK1698640T4 (da) 2003-10-01 2004-10-01 Fremgangsmåde til stabilisering af antistof og antistofpræparat som stabiliseret opløsning.

Country Status (16)

Country Link
US (3) US8496930B2 (da)
EP (2) EP1698640B2 (da)
JP (1) JP4219932B2 (da)
KR (1) KR100911091B1 (da)
CN (1) CN100522998C (da)
AU (1) AU2004277466C1 (da)
CA (1) CA2540848C (da)
CY (1) CY1117215T1 (da)
DK (1) DK1698640T4 (da)
ES (1) ES2562912T5 (da)
HK (1) HK1090933A1 (da)
HU (1) HUE026793T2 (da)
PL (1) PL1698640T5 (da)
PT (1) PT1698640E (da)
SI (1) SI1698640T2 (da)
WO (1) WO2005033143A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
AU2004277466C1 (en) 2003-10-01 2022-06-23 Kyowa Kirin Co., Ltd. Method of stabilizing antibody and stabilized solution-type antibody preparation
CA2607663C (en) * 2005-05-19 2014-08-12 Amgen Inc. Compositions and methods for increasing the stability of antibodies
MX2008001068A (es) * 2005-07-29 2008-03-19 Amgen Inc Formulacion que inhibe la agregacion de proteina.
GEP20125628B (en) * 2006-04-21 2012-09-10 Novartis Ag Pharmaceutical compositions containing antagonist anti-cd40 antibody
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
SG177982A1 (en) * 2007-01-16 2012-02-28 Abbott Lab Methods for treating psoriasis
US8168760B2 (en) 2007-03-29 2012-05-01 Abbott Laboratories Crystalline anti-human IL-12 antibodies
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
NZ602498A (en) * 2007-11-30 2014-08-29 Abbvie Inc Protein formulations and methods of making same
EP2274333A4 (en) * 2008-03-18 2011-06-15 Abbott Lab PROCESS FOR TREATING PSORIASIS
NZ592644A (en) * 2008-11-28 2013-09-27 Abbott Lab Stable antibody compositions and methods for stabilizing same
NZ595694A (en) * 2009-05-04 2013-09-27 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
SI2437782T1 (sl) 2009-06-04 2013-12-31 Alk Ag Stabiliziran sestavek, ki obsega vsaj eno adrenergično spojino
RU2012114854A (ru) * 2009-09-14 2013-10-27 Эбботт Лэборетриз Способы лечения псориаза
EP3708190A1 (en) 2010-02-26 2020-09-16 Novo Nordisk A/S Stable antibody containing compositions
CA3101298A1 (en) 2010-03-01 2011-09-09 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
US20130136733A1 (en) 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
AR083035A1 (es) * 2010-09-17 2013-01-30 Baxter Int ESTABILIZACION DE INMUNOGLOBULINAS MEDIANTE UNA FORMULACION ACUOSA CON HISTIDINA A pH ACIDO DEBIL A NEUTRO, COMPOSICION ACUOSA DE INMUNOGLOBULINA
TWI603739B (zh) 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EP2949336B1 (en) 2013-01-28 2018-09-05 National University Corporation Kumamoto University Stabilized protein gel preparation
CN105377237B (zh) * 2013-07-19 2019-04-19 德国赫素制药集团 使免疫反应的调节与生物药品的给药相关的方法和制剂
CN103772505B (zh) * 2013-12-18 2014-10-15 长春博迅生物技术有限责任公司 一种抗体试剂保存液
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
EP3419663A1 (en) * 2016-02-24 2019-01-02 Visterra, Inc. Formulations of antibody molecules to influenza virus
WO2017170626A1 (ja) * 2016-03-30 2017-10-05 千寿製薬株式会社 水性液剤
CR20210435A (es) 2019-02-18 2021-09-20 Lilly Co Eli Formulación de anticuerpos terapéuticos
AU2020248404A1 (en) 2019-03-25 2021-09-30 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN114746439A (zh) * 2019-10-11 2022-07-12 雷迪博士实验室有限公司 整合蛋白抗体的稳定制剂

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US421777A (en) * 1890-02-18 Straining-pot
JPH0669961B2 (ja) 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
JPS62194459A (ja) 1986-02-21 1987-08-26 Sankyo Co Ltd 固相化試薬の安定化剤
JPS62244441A (ja) 1986-04-16 1987-10-24 Green Cross Corp:The 抗体固定化担体
DE3734923C1 (de) * 1987-10-15 1989-01-26 Biotest Pharma Gmbh Verfahren zur Herstellung einer sterilen Plasmaproteinloesung,die Fibrinogen und den Gerinnungsfaktor XIII enthaelt
WO1989011298A1 (en) 1988-05-27 1989-11-30 Centocor, Inc. Formulation for antibody reagents
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
JP2966592B2 (ja) * 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
AU679913B2 (en) * 1992-04-30 1997-07-17 Millennium Pharmaceuticals, Inc. Stable polypeptide composition
JPH06189781A (ja) * 1992-12-25 1994-07-12 Mitsui Toatsu Chem Inc 培養液中の生理活性タンパク質の安定化方法
FR2708467B1 (fr) * 1993-07-30 1995-10-20 Pasteur Merieux Serums Vacc Préparations d'immunoglobulines stabilisées et procédé pour leur préparation.
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
DE69632949T2 (de) 1995-03-10 2005-07-28 Genentech, Inc., South San Francisco Die aktivierung von rezeptoren durch gas6
AU2444899A (en) * 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
WO2000066160A1 (fr) * 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation
EP1050307A1 (en) * 1999-05-06 2000-11-08 Applied Research Systems ARS Holding N.V. CCR4 antagonists in sepsis
CN100381172C (zh) 1999-06-25 2008-04-16 吉尼泰克公司 使用抗-ErbB2抗体治疗前列腺癌
AU784187B2 (en) 1999-09-30 2006-02-16 Kyowa Hakko Kogyo Co. Ltd. Human type complementarity determining region transplantation antibody against ganglioside GD3 and derivatives of antibody against ganglioside GD3
EP1254666A4 (en) 1999-12-28 2004-12-22 Chugai Pharmaceutical Co Ltd STABLE ANTIBODY COMPOSITIONS AND INJECTION FORMULATIONS
CN100455599C (zh) 2000-03-03 2009-01-28 协和发酵工业株式会社 基因重组抗体及其抗体片段
JP5485489B2 (ja) * 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
EP1449850B9 (en) 2001-08-31 2011-05-11 Kyowa Hakko Kirin Co., Ltd. Human cdr-grafted antibodies and antibody fragments thereof
JP2005522996A (ja) 2001-11-02 2005-08-04 セントカー・インコーポレーテツド Ｒｓｖタンパク質、抗体、組成物、方法および使用
EP3192528A1 (en) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
AU2004277466C1 (en) * 2003-10-01 2022-06-23 Kyowa Kirin Co., Ltd. Method of stabilizing antibody and stabilized solution-type antibody preparation

Also Published As

Publication number Publication date
AU2004277466C1 (en) 2022-06-23
CN100522998C (zh) 2009-08-05
PT1698640E (pt) 2016-03-31
US8496930B2 (en) 2013-07-30
HK1090933A1 (zh) 2007-01-05
SI1698640T1 (sl) 2016-03-31
ES2562912T5 (es) 2020-02-18
HUE026793T2 (en) 2016-07-28
EP1698640B2 (en) 2019-06-19
DK1698640T3 (da) 2016-02-15
US20150190507A1 (en) 2015-07-09
PL1698640T3 (pl) 2016-05-31
US10172790B2 (en) 2019-01-08
AU2004277466A1 (en) 2005-04-14
SI1698640T2 (sl) 2019-08-30
EP3006463A1 (en) 2016-04-13
US20070020255A1 (en) 2007-01-25
KR20060089227A (ko) 2006-08-08
CY1117215T1 (el) 2017-04-05
US20130280248A1 (en) 2013-10-24
CA2540848A1 (en) 2005-04-14
KR100911091B1 (ko) 2009-08-06
AU2004277466B2 (en) 2010-04-01
WO2005033143A1 (ja) 2005-04-14
ES2562912T3 (es) 2016-03-09
CA2540848C (en) 2012-12-11
EP1698640A1 (en) 2006-09-06
EP1698640B1 (en) 2015-12-30
EP1698640A4 (en) 2008-09-17
JPWO2005033143A1 (ja) 2007-11-15
JP4219932B2 (ja) 2009-02-04
CN1856507A (zh) 2006-11-01
PL1698640T5 (pl) 2019-12-31
US9011850B2 (en) 2015-04-21

Similar Documents

Publication Publication Date Title
DK1698640T4 (da) Fremgangsmåde til stabilisering af antistof og antistofpræparat som stabiliseret opløsning.
DK1575416T3 (da) Fremgangsmåder til diagnosticering af præeklampsi
DK1504126T3 (da) Fremgangsmåde til regulering af genekspression
DK1748077T3 (da) Fremgangsmåde til fremstilling af protein
DK1427730T3 (da) Nye dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
DK2929891T3 (da) Fremgangsmåde til modulering af appetitten
DK1414803T3 (da) Pyrazolylcarboxanilider som fungicider
DK1451143T3 (da) Fremgangsmåder til fremstilling af O-desmethylvenlafaxin
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK1907373T3 (da) Fremgangsmåder til fremstillingen af 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dionforbindelser
DK2508521T4 (da) Dimaleat af en aminocrotonylforbindelse og fremgangsmåde til fremstilling deraf
DK2135957T3 (da) Fremgangsmåde til fremstilling af glucaner
DK1549341T3 (da) Mod vævsfaktor rettede antistoffer som antikoagulanter
DK1638928T3 (da) N-alkynyl-2-(substituerede aryloxy)alkylthio-amidderivater som fungicider
NL1027608A1 (nl) Automatisch uitlijnend scintillator-collimatorsamenstel.
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
DK1713801T3 (da) Fremgangsmåde til fremstilling af 1-(2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amin
DK1536685T4 (da) Fremgangsmåde til fremstilling af pasta-ekstruderede sulfonamidsammensætninger
DK1611884T3 (da) Plaster, indeholdende diclofenac
DK1831223T3 (da) Fremgangsmåde til fremstilling af L-biopterin
DK1915884T3 (da) Fremgangsmåde til betjening af en kommunikationsindretning og et kommunikationssystem, en kommunikationsindretning og et system, som indbefatter kommunikationsindretningen
DK1768691T3 (da) Aequorinholdige præparater og fremgangsmåder til anvendelse af samme
ITMO20020337A1 (it) Dispositivo per anastomosi.
DK1399016T3 (da) Fremgangsmåde til generering af diversitet